Caribou Biosciences, Inc. (CRBU)
NASDAQ: CRBU · Real-Time Price · USD
2.030
+0.090 (4.64%)
At close: May 11, 2026, 4:00 PM EDT
2.050
+0.020 (0.99%)
After-hours: May 11, 2026, 7:43 PM EDT
Caribou Biosciences Revenue
Caribou Biosciences had revenue of $2.40M in the quarter ending March 31, 2026, with 1.87% growth. This brings the company's revenue in the last twelve months to $11.20M, up 12.96% year-over-year. In the year 2025, Caribou Biosciences had annual revenue of $11.16M with 11.66% growth.
Revenue (ttm)
$11.20M
Revenue Growth
+12.96%
P/S Ratio
17.80
Revenue / Employee
$115,495
Employees
97
Market Cap
199.47M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 11.16M | 1.17M | 11.66% |
| Dec 31, 2024 | 9.99M | -24.48M | -71.01% |
| Dec 31, 2023 | 34.48M | 20.63M | 148.91% |
| Dec 31, 2022 | 13.85M | 4.25M | 44.31% |
| Dec 31, 2021 | 9.60M | -2.76M | -22.35% |
| Dec 31, 2020 | 12.36M | 6.57M | 113.56% |
| Dec 31, 2019 | 5.79M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MacroGenics | 149.50M |
| Karyopharm Therapeutics | 146.07M |
| Precision BioSciences | 45.07M |
| Atrium Therapeutics | 18.62M |
| Tonix Pharmaceuticals Holding | 17.56M |
| MediWound | 16.96M |
| Whitehawk Therapeutics | 7.15M |
| Oramed Pharmaceuticals | 2.00M |
CRBU News
- 14 hours ago - Caribou Biosciences price target raised to $11 from $9 at H.C. Wainwright - TheFly
- 4 days ago - Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 6 days ago - Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference - GlobeNewsWire
- 5 weeks ago - Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy - GlobeNewsWire
- 2 months ago - Caribou Biosciences Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Caribou Biosciences price target raised to $13 from $11 at Evercore ISI - TheFly
- 2 months ago - Caribou Biosciences reports Q4 EPS (28c) vs. (39c) last year - TheFly
- 2 months ago - Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire